Hylvastam

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is a buffering agent presented as a solution for injection for intravenous use. It is used to correct acid‑base disturbances in adult patients. GNH USA supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Hylvastam is an intravenous buffering solution used in disorders of acid‑base balance and related emergency situations. - Metabolic acidosis: restores normal blood pH by providing bicarbonate ions. - Hyperkalemia: promotes intracellular shift of potassium, aiding in rapid potassium reduction. - Cardiac arrest: used during resuscitation to counteract severe acidosis and improve myocardial function.

Adverse reactions may occur with intravenous administration of Hylvastam.

Common Side Effects: - Injection site pain or irritation. - Mild hypernatremia due to sodium load. - Transient metabolic alkalosis. - Fluid overload in patients with limited cardiac reserve. - Mild hypotension from rapid infusion. - Hypocalcemia secondary to alkalosis.

Serious or Rare Side Effects: - Severe metabolic alkalosis leading to respiratory depression. - Pulmonary edema in volume‑overloaded patients. - Cardiac arrhythmias from electrolyte shifts. - Severe hypernatremia causing neurologic symptoms. - Anaphylactic or severe hypersensitivity reactions. - Intracranial hemorrhage in patients with rapid pH shifts.

Careful assessment and monitoring are required when using Hylvastam. - Monitor serum electrolytes: check sodium, potassium, calcium, and bicarbonate levels before and after infusion. - Assess acid‑base status: obtain arterial blood gas to guide dosing. - Adjust dose in renal impairment: reduced clearance may increase risk of alkalosis. - Use caution in heart failure or fluid‑overload states: limit infusion volume and rate. - Avoid rapid bolus administration: infuse slowly to prevent sudden pH changes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated prior to administration.

Major Interactions (Avoid): - Calcium‑containing solutions: may precipitate and cause catheter blockage. - Concurrent alkalinizing agents (e.g., other bicarbonate preparations): risk of severe metabolic alkalosis. - Loop diuretics combined with high bicarbonate doses: can exacerbate electrolyte disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal clearance of bicarbonate, increasing alkalosis risk. - Potassium‑sparing diuretics: monitor potassium levels closely. - Certain antibiotics (e.g., aminoglycosides): altered efficacy at high pH. - ACE inhibitors or ARBs: may affect renal handling of sodium and bicarbonate.